Anti-Microbial Nasal Spray Effective Against COVID-19 in Nonhospitalized Patients, Study Shows
Glenmark Pharmaceuticals reported that its anti-microbial nitric oxide nasal spray (NONS) had positive results in a phase 3 trial in 306 nonhospitalized adult Indian patients with COVID-19.
The anti-microbial spray reduced viral load by 94 percent in 24 hours and by 99 percent in 48 hours when compared to saline nasal spray, the company said.
Glenmark, which received marketing approval from India’s drug regulator for NONS in an accelerated approval process, plans to market NONS under the brand name FabiSpray in India. The company also plans to launch the product in other Asian markets in partnership with SaNOtize Research & Development.